v3.26.1
Debt - Liability for Sale of Future Royalties Narrative (Details) - A&R Royalty Purchase Agreement
$ in Millions
6 Months Ended
Jun. 30, 2026
USD ($)
item
Assigned royalty payments  
Aggregate upfront cash consideration received for sale of future royalties $ 2,100.0
Future royalties sold percentage 100.00%
Potential purchase price payments | item 3
Royalty Pharma Receives Greater Than $347 Million of Assigned Royalties in 2027  
Assigned royalty payments  
Contingent purchase price payments $ 20.0
Assigned royalty payments 347.0
Royalty Pharma Receives Greater Than $363 Million of Assigned Royalties in 2028  
Assigned royalty payments  
Contingent purchase price payments 20.0
Assigned royalty payments 363.0
Royalty Pharma Receives Greater Than $379 Million of Assigned Royalties in 2029  
Assigned royalty payments  
Contingent purchase price payments 20.0
Assigned royalty payments $ 379.0